Tagged with novartis

Switzerland The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over five million more likely to follow. Elsewhere, Swiss health insurance premiums are set to see their largest rise since 2010…

Egypt Sherif Amin, an 18-year industry veteran with 12 years of experience in oncology leadership roles across MEA, is the recipient of several awards, including the 2019 Oncology President Award, 2015 CEO Innovation Award, and 2014 MENA Leadership Award. A recent appointee as country president for Novartis Egypt, Amin describes how…

Global The FDA’s recent accelerated approval for Bluebird Bio’s gene therapy Skysona and its US list price of USD three million per treatment has reignited the global debate around drug pricing. Bluebird execs are keen to emphasise how life-changing such treatments are for a small number of patients; Skysona is indicated…

Singapore On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population. Speaking at the outset…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…

China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…

USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…

Global Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis has announced a major restructuring; this time, too, citing financial motives.   The Swiss giant – fifth in the global…

Ukraine Russia’s invasion of Ukraine has been roundly condemned by the pharmaceutical industry and almost all Big Pharmas have pledged humanitarian support to Ukraine. However, not all companies have followed the lead of businesses in other industries in severing ties with Russia, citing the importance of continuing to supply essential medicines…

Global Pfizer’s record-breaking year set the stage for a sound financial year for Big Pharma’s top ten, whose revenue grew on average 19.8 percent in 2021. Posting sales of over USD 80 billion, Pfizer pulled away from second placed Roche and is aiming to break the USD 100 billion barrier in…

Global Recent reportage from Global Data Research and Clinical Trials Arena has ranked the world’s leading biopharma companies best positioned to take advantage of future biosimilars disruption. The ranking considers the number of jobs listed by each company mentioning biosimilars, deals conducted, and company filing mentions in the period between January…